Striatal Dopamine Transporter Availability is Associated with Sleep Disturbance among Patients with Bipolar I Disorder: A Single-photon Emission Computed Tomography Study Using [99mTc] TRODAT-1

Tsung-Hua Lu¹, Shih-Hsien Lin¹,², Huai-Hsuan Tseng¹,², Yen Kuang Yang¹,²,³, Nan Tsing Chiu⁴, Po See Chen¹,²
¹Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, ²Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, ³Department of Psychiatry, Tainan Hospital, Ministry of Health and Welfare, ⁴Department of Nuclear Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Objective: Bipolar disorder (BD) is characterized by the poor sleep quality. Whether the striatal dopamine transporter (DAT) availability is related to sleep quality among patients with BD is unclear.

Methods: Fifty-three euthymic patients with BD (24 BD-I and 29 BD-II) and sixty-eight healthy controls were enrolled. The Chinese Version of the Pittsburgh Sleep Quality Index (PSQI) was used, and the availability of DAT was assessed by single-photon emission computed tomography (SPECT) using [99mTc] TRODAT-1.

Results: The sleep disturbance component of the PSQI was significantly associated with the level of DAT availability among patients with BD.

Conclusion: The striatal dopaminergic activity that contributes to resilience to adversity was associated with sleep pattern among patients with BD.

KEY WORDS: Bipolar disorder; Dopamine; Tomography, emission-computed, single-photon; Sleep.

INTRODUCTION

Sleep plays a vital role in bipolar disorder (BD) [1,2]. BD patients experiencing a manic episode have a shorter rapid eye movement (REM) latency, an increased REM density, increased REM activity, a shorter sleep duration, and later sleep onset [1]. While there is a remarkable lack of consensus with regard to BD patients within a depressive episode [2]. Meanwhile, a longer sleep latency, shorter sleep duration, longer wake time after sleep onset, poor sleep efficiency, and greater night-to-night variability of sleep pattern were found to be characteristics of a remitted BD sample [3,4].

The dysregulation of dopamine plays an important role in different types and stages of BD [5]. The dopamine transporter (DAT) availability is significantly altered in BD patients [6]. Moreover, a role of the dopaminergic system in modulating the sleep-wake cycle has been confirmed by animal study [7]. In healthy controls (HCs), a decrease in dopamine reuptake due to a lower DAT availability could cause a shorter sleep duration [8]. In addition, sleep disturbance is present in patients with various dopamine-related diseases [9,10].

Regardless this evidence imply that sleep disturbance may be associated with DAT availability among patients with BD, whether there is an association between dopamine function and sleep disturbance among patients with BD is unclear. Here, the primary theoretical-driven aim is to test the relationship between striatal DAT availability and sleep disturbance in patients with BD in the euthymic state. As little is known on the association between striatal DAT with other domains of sleep quality
among BD-I and BD-II, the second aim is to probe these associations.

**METHODS**

**Ethics Statement**

The Institutional Review Board for the Protection of Human Subjects at National Cheng Kung University Hospital approved the research protocol (B-BR-105-086). Patients were recruited from the Psychiatric Outpatient Department of National Cheng Kung University Hospital, and healthy subjects were recruited via internet and public advertisements. Signed written informed consent forms were obtained from all enrolled subjects after the protocol had been fully explained.

**Enrollment and Measurements of Psychopathology in Participants**

In this study, we enrolled 53 euthymic patients with BD based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) who had been receiving mood stabilizer treatment at the Department of Psychiatry of National Cheng Kung University Hospital. Eligible individuals were those aged between 18−70 years. Patients were receiving mood-stabilizer treatment, including valproic acid (VPA) or lithium (n = 14 [26.4%]), VPA + antipsychotics (n = 29, [54.7%]), antipsychotics (n = 8, [15.1%]), and other treatments (including selective serotonin receptor inhibitors [SSRI] or no medication use) (n = 2, [3.8%]). The Hamilton Depression Rating Scale (HDRS) and the Young Mania Rating Scale (YMRS) were used to evaluate the psychopathology of the patients by psychiatrists. The exclusion criteria included (i) a diagnosis of organic mood disorder, (ii) mood disorder not otherwise specified, (iii) more than one lifetime course of electroconvulsive therapy (ECT) or ECT within the last 6 months, (iv) cerebrovascular disease, (v) neurodegenerative disorder, and (vi) macrovascular disorder.

Sixty-eight HCs were enrolled as the control group in this study. The exclusion criteria included (i) serious surgical treatment or physical illness, (ii) individuals who were pregnant or breastfeeding, (iii) substance abuse within the past three months identified based on the DSM-5 criteria, (iv) previous receipt of any psychotropic agent, and (v) an organic mental disease, mental retardation or dementia.

**Chinese Version of the Pittsburgh Sleep Quality Index (PSQI)**

The PSQI contains 19 self-rated questions yielding seven components [11]. Each component is scored on a scale of 0 to 3, yielding a global PSQI score ranging between 0 and 21, with higher scores indicating a poorer sleep quality. This questionnaire has a diagnostic sensitivity of 90% and a specificity of 87% between good and poor sleepers [11]. The Chinese version of the PSQI has been documented as reliable and valid [12].

**[^99mTc] TRODAT-1 Single-photon Emission Computed Tomography (SPECT)**

Each subject was given an intravenous injection of 740 MBq (20 mCi) [^99mTc] TRODAT-1 in a quiet environment about ten minutes after inserting an intravenous line. The SPECT data were obtained with an energy window of 15% centered on 140 keV for [^99mTc]. Imaging of [^99mTc] TRODAT-1 started about 240 minutes after injection, and SPECT images were acquired over a circular 360 rotation in 120 steps, 50 sec/step, in a 128 × 128 × 16 matrix. Butterworth and Ramp filters (cut-off frequency = 0.3 Nyquist; power factor = 7) were then used to rebuild the images using the attenuated approach of Chang’s method, and the reconstructed cross-sectional images were re-adjusted to be parallel to the canthomeatal line. Each transverse image had a slice thickness of 2.89 mm. Additionally, all subjects underwent magnetic resonance imaging (MRI) (Signa CV-I, 1.5 Tesla; GE Healthcare, Milwaukee, WI, USA). The SPECT image of each subject was automatically co-registered with the corresponding T2-weighted MRI image using PMOD software (PMOD Technologies, Zurich, Switzerland), and then manually adjusted by an experienced nuclear medicine doctor. The MRI image was used as a reference, so the slice thickness of the co-registered image was the thickness of the T2-weighted MRI image (3.3 mm). For co-registration, the rigid transformation was defined by 6 parameters, the rotation angle and translation distance in the three spatial directions. The interpolation method was the trilinear interpolation approach. On the co-registered images, the two adjacent transverse slices containing the strongest striatal radioactivity were further checked to determine whether the SPECT and MRI images were accurately co-registered and whether the striatum was best seen on the two slices of the MRI images. If this was not the case, co-registration was
further manually adjusted until a satisfactory result was achieved. Region of interest (ROIs) were then drawn on the two adjacent MRI cross sections. The difference between the average activity of the striatum (St) and the average activity of the occipital cortex (Oc) was divided by the average activity of the Oc to obtain the radioactivity ratio [(St – Oc) / Oc ratio] [13,14].

### Statistical Analysis

Analysis of covariance (ANOVA) was used to test the group differences. Fisher’s least significant difference was tested when performing post-hoc analyses. As age and smoking status may be associated with DAT and sleep quality, a series of partial correlations, controlling the effect of age [15] and smoking status [16], were used to probe the association between sleep quality and DAT availability. A supplemental nonparametric correlation test was conducted to test the robustness of the significant finding. Statistical analyses were conducted using SPSS 22.0 (IBM Co., Armonk, NY, USA). Significance was assumed at $p < 0.05$. For the secondary aims of analysis, we controlled the $p$ value due to multiple comparison.

### RESULTS

The demographic and clinical characteristics of the participants are shown in Table 1. The patients with BD had a higher YMRS score and a poorer PSQI score. For the

### Table 1. Demographic and clinical characteristics of the participants

| Variable                  | HCs (n = 68) | BD-I (n = 24) | BD-II (n = 29) | Test statistic | Post-hoc |
|---------------------------|-------------|--------------|---------------|----------------|----------|
| Sex (M/F)                 | 28/40       | 10/14        | 15/14         | 0.97           | 0.64     |
| Smoking (yes/no)          | 7/61        | 3/21         | 7/22          | 3.29           | 0.193    |
| Age (yr)                  | 33.63 ± 11.33 | 40.54 ± 14.75 | 35.48 ± 12.07 | 2.83           | 0.063    |
| HDRS                      | 1.65 ± 1.55 | 1.38 ± 1.56  | 2.45 ± 2.34   | 2.88           | 0.060    |
| YMRS                      | 0.06 ± 0.49 | 0.96 ± 1.65  | 0.76 ± 1.21   | 9.40           | 0.000    |
| DAT availability          | 1.39 ± 0.25 | 1.39 ± 0.27  | 1.41 ± 0.19   | 0.05           | 0.952    |
| PSQI                      |             |              |               |                |          |
| Sleep quality C1          | 0.94 ± 0.64 | 1.25 ± 0.53  | 1.48 ± 0.78   | 7.31           | 0.001    |
| Sleep latency C2          | 0.96 ± 0.87 | 1.17 ± 0.96  | 1.66 ± 0.90   | 6.19           | 0.003    |
| Sleep duration C3         | 0.72 ± 0.67 | 0.29 ± 0.55  | 0.59 ± 0.82   | 3.47           | 0.034    |
| Sleep efficiency C4       | 0.16 ± 0.48 | 0.46 ± 1.02  | 0.48 ± 1.06   | 2.40           | 0.095    |
| Sleep disturbance C5      | 0.99 ± 0.40 | 1.21 ± 0.66  | 1.48 ± 0.74   | 8.38           | 0.000    |
| Use of sleeping medication C6 | 0.04 ± 0.21 | 1.88 ± 1.30  | 2.10 ± 1.35   | 73.37          | 0.000    |
| Daytime dysfunction C7    | 0.59 ± 0.58 | 0.92 ± 0.83  | 1.72 ± 0.84   | 26.64          | 0.000    |
| Sum                       | 4.40 ± 2.19 | 7.17 ± 2.46  | 9.52 ± 3.77   | 38.64          | 0.000    |

Values are presented as number only or mean ± standard deviation.

HCs, healthy controls; BD, bipolar disorder; HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; DAT, dopamine transporter; PSQI, Pittsburgh Sleep Quality Index.

### Table 2. Partial correlation, controlling for age and smoking status, between DAT availability and PSQI component scores

| PSQI                     | HCs (n = 68) | BD (n = 53) | BD-I (n = 24) | BD-II (n = 29) |
|--------------------------|-------------|-------------|---------------|----------------|
|                          | $r$        | $p$ value   | $r$           | $p$ value      | $r$        | $p$ value   |
| Sleep quality C1         | 0.18        | 0.150       | 0.23          | 0.107          | 0.03       | 0.895       | 0.30         | 0.133         |
| Sleep latency C2         | -0.19       | 0.120       | 0.06          | 0.653          | -0.20      | 0.361       | 0.35         | 0.071         |
| Sleep duration C3        | 0.03        | 0.807       | 0.06          | 0.676          | 0.22       | 0.333       | 0.07         | 0.731         |
| Sleep efficiency C4      | -0.15       | 0.243       | 0.16          | 0.269          | 0.14       | 0.548       | 0.25         | 0.216         |
| Sleep disturbance C5     | 0.00        | 0.976       | 0.32          | 0.021          | 0.40       | 0.067       | 0.12         | 0.568         |
| Use of sleeping medication C6 | 0.03        | 0.807       | -0.01         | 0.918          | 0.01       | 0.950       | 0.00         | 0.983         |
| Daytime dysfunction C7   | 0.01        | 0.929       | 0.08          | 0.560          | 0.07       | 0.742       | 0.20         | 0.319         |
| Sum                      | -0.04       | 0.743       | 0.21          | 0.144          | 0.15       | 0.511       | 0.30         | 0.134         |

DAT, dopamine transporter; PSQI, Pittsburgh Sleep Quality Index; HCs, healthy controls; BD, bipolar disorder.
primary hypothesis, a significant association between sleep disturbance component of the PSQI and striatal DAT availability was found in the patients with BD (partial $r = 0.32, p = 0.021$). For the secondary exploratory aim of this study, no significant association was found after controlling for the multiple comparison (Table 2).

**DISCUSSION**

Our study showed that euthymic BD patients had higher PSQI than healthy controls. This is compatible with other studies showing that residual sleep problems is common in euthymic BD patients [3,4,17].

The sleep disturbance component in PSQI had a positive association with DAT availability in euthymic BD patient in this study. The result is different from a previous study with healthy controls that showed lower DAT linked to decreased sleep duration [8]. Both results together imply a possible role of striatal dopamine homeostasis in sleep regulation. In healthy controls, when the DAT availability is low, dopamine might be accumulated in the synaptic. In BD patients, higher DAT availability might link to (i) increased phasic dopamine release from the presynaptic neuron; or (ii) lower tonic dopamine release with super-sensitivity of postsynaptic dopamine receptors [6].

The PSQI sleep disturbance subscale (C5) is composed of eight items related to symptoms that disturb one’s sleep, such as difficult falling asleep, sleep fragmentation, sleep-breathing disorder, sensorial discomfort and nightmare. The scores of this component might indicate a higher REM duration and a long night waking time [18]. With the higher DAT availability in BD, greater dopamine release could inhibit slow wave sleep and enhance REM sleep, resulting in sleep disturbance [19].

The current studies about the DAT availability in BD showed controversial results [5]. In this study, the DAT availability had no significant difference between healthy controls and medication-treated BD patients. This was different from the results of our previous research that showed the DAT availability was significantly higher in patients with medication-free euthymic bipolar disorder [6]. However, another study observed a downregulation of DAT at the dorsal caudate in unmedicated euthymic BD patients, and there was no difference in the striatum [20]. We speculate that medications used to treat BD could modulate DAT availability [21], including antipsychotics, antidepressants and mood stabilizers which might up-regulate or down-regulate the DAT availability in different type of BD, number of episodes, and duration of illness.

In conclusion, the sleep problem was still persistent and prominent in BD patients even achieving remission. Sleep disturbance in PSQI subscales was positively associated with DAT availability in the remitted BD-I patients. Understanding the relationship between DAT and sleep problems in different stage and type of BD is important.

**Limitations**

First, the study was cross-sectional, and thus causal relationships cannot be inferred. Second, sleep quality was measured using a subjective questionnaire.

**Funding**

This work was supported by the Ministry of Science and Technology, Taiwan (MOST 104-2321-B-006-031, MOST 106-2410-H-468-012-MY2, MOST 107-2314-B-006-006-082, MOST 107-2628-B-006-005-, MOST 108-2320-B-006-004-, MOST 108-2410-H-468-009, and MOST 109-2628-B-006-004-) and National Cheng Kung University Hospital (NCKUH-10704010 and NCKUH-10902014).

**Acknowledgments**

The authors are indebted to the research participants and Professor Yuan-Hwa Chou from Taipei Veterans General Hospital.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.

**Author Contributions**

Study design: Po See Chen, Nan Tsing Chiu. Statistical analysis: Shih-Hsien Lin. Data collection: Tsung-Hua Lu, Huai-Hsuan Tseng, Yen Kuang Yang, Po See Chen. Writing—original draft: Tsung-Hua Lu. Writing—protocol: Po See Chen. All authors interpreted the analysis of the results and helped to revise the manuscript.

**ORCID**

Tsung-Hua Lu https://orcid.org/0000-0003-1579-3165
Shih-Hsien Lin https://orcid.org/0000-0001-9904-8300
Huai-Hsuan Tseng https://orcid.org/0000-0002-5213-1585
REFERENCES

1. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008;165:820-829.

2. Steinan MK, Scott J, Lagerberg TV, Melle I, Andreassen OA, Vaaler AE, et al. Sleep problems in bipolar disorders: more than just insomnia. Acta Psychiatr Scand 2016;133:369-377.

3. Geoffroy PA, Scott J, Boudebesse C, Lajnef M, Henry C, Leboyer M, et al. Sleep in patients with remitted bipolar disorders: a meta-analysis of actigraphy studies. Acta Psychiatr Scand 2015;131:89-99.

4. Rocha PM, Neves FS, Corrêa H. Significant sleep disturbances in euthymic bipolar patients. Compr Psychiatry 2013;54:1003-1008.

5. Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 2017;22:666-679.

6. Chang TT, Yeh TL, Chiu NT, Chen PS, Huang HY, Yang YK, et al. Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [99mTc] TRODAT-1. Bipolar Disord 2010;12:102-106.

7. Isaac SO, Berrihde CW. Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J Pharmacol Exp Ther 2003;307:386-394.

8. Chiu NT, Lee BF, Yeh TL, Chen PS, Lee IH, Chen KC, et al. Relationship between striatal dopamine transporter availability and sleep quality in healthy adults. Mol Imaging Biol 2011;13:1267-1271.

9. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson’s disease treatment. Lancet 2000;355:1333-1334.

10. Wieand M, Möller AA, Lauer C, Stolz S, Schreiber W, Dose M, et al. Nocturnal sleep in Huntington's disease. J Neurol 1991;238:203-208.

11. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.

12. Chen ML, Lin LC, Wu SC, Lin JG. The effectiveness of acupuncture in improving the quality of sleep of institutionalized residents. J Gerontol A Biol Sci Med Sci 1999;54:M389-M394.

13. Chen PS, Yeh TL, Lee IH, Lin CB, Tsai HC, Chen KC, et al. Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers--a SPECT study. Neuroimage 2011;56:1526-1530.

14. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson’s disease. J Nucl Med 2004;45:207-213.

15. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554-559.

16. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB, et al. Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:274-279.

17. Boudebesse C, Henry C. [Emotional hyper-reactivity and sleep disturbances in remitted patients with bipolar disorders]. Encephale 2012;38 Suppl 4:S173-S178. French.

18. Harvey AG, Talbot LS, Gershon A. Sleep disturbance in bipolar disorder across the lifespan. Clin Psychol (New York) 2009;16:256-277.

19. Kesner AJ, Lovinger DM. Wake up and smell the dopamine: new mechanisms mediating dopamine activity fluctuations related to sleep and psychostimulant sensitivity. Neuropsychopharmacology 2021;46:683-684.

20. Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng QH, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord 2011;13:406-413.

21. Hsueh YS, Lin CY, Chiu NT, Yang YK, Chen PS, Chang HH. Changes in striatal dopamine transporters in bipolar disorder and valproate treatment. Eur Psychiatry 2021;64:e9.